PIK3CD and acute lymphoblastic leukemia: Therefore, in the present study, the cell-biological and molecular effects of the PI3K-inhibitor IDEL in mono- and combined drug application with the conventionally used cytostatics cytarabine (AraC) and dexamethasone (DEX) on pro-B-ALL cells were investigated.